VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors Bridgewater, NJ

Announces the Appointment of Patrick G. LePore to its Board of Directors

Bridgewater, NJ - September 14, 2020 - VYNE

Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that the Board of Directors

of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020.

"We are delighted to welcome Pat to our Board. Pat brings

extensive experience from a long and successful career as a senior level executive and board member for several highly regarded

companies in the pharmaceutical sector," said David Domzalski, President and Chief Executive Officer of VYNE. "As VYNE

establishes itself as a commercial stage pharmaceutical company, it is important to have Board members with the appropriate areas

of expertise. Pat has relevant experience in M&A, operations and the sales and marketing of branded pharmaceuticals, which

will be very helpful as we make preparations for our second commercial launch in 2020 and build our franchise in dermatology. We

are confident that he will bring valuable insight and make important contributions to our company."

Mr. LePore stated "I am enthusiastic to be joining

the Board of Directors of VYNE, and to work with a highly dedicated organization. VYNE is committed to making a meaningful

difference in the lives of patients, and has a strong culture of innovation, a recent track record of regulatory approvals

and a great opportunity to build valuable therapeutic brands."

Mr. LePore has more than 40 years of experience in the

pharmaceutical industry, in both private and public sectors, and with board and operational experience in each. He served as

Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September

2006 to 2012. During his tenure at Par, Mr. LePore oversaw the management of over 2,000 employees with facilities across the

United States and India. He also directed the growth of its brand business, Strativa, its sales force and the acquisition of

several specialty pharmaceutical products. Through Mr. LePore's leadership, Par increased its value and market presence

culminating in its sale to affiliates of TPG Capital for approximately $2 billion in 2012. He remained as chairman of the new

company through its sale to Endo International for approximately $8 billion in 2015. Mr. LePore began his career with

Hoffmann-LaRoche in 1978 as a sales representative. Later, he founded and took public Boron, LePore & Associates, a

medical communications company, which was eventually sold to Cardinal Health. Mr. LePore is currently Chairman of the Board

of Lannett Co. Inc., the Vice Chairman of the Board of Matinas BioPharma and is a trustee of Villanova University. Mr. LePore

earned a bachelor's degree from Villanova University and a Master of Business Administration from Fairleigh Dickinson

- 2nd Floor - Bridgewater, NJ 08807

About VYNE Therapeutics Inc.

VYNE Therapeutics' mission is to improve the lives of

patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard,

VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST ),

and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, the world's first topical minocycline,

and for ZILXI (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by

the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ's Full Prescribing Information

at amzeeq.com and ZILXI's Full Prescribing Information at zilxi.com.

more information about VYNE Therapeutics Inc. or its investigational products, visit www. vynetherapeutics.com or follow VYNE

on Twitter. VYNE may use its website to comply with its

disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE's website in addition to following

its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

LifeSci Advisors, LLC

Chief Financial Officer

- 2nd Floor - Bridgewater, NJ 08807

Cautionary Statement Regarding Forward-Looking Statements

This release includes forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the

development and commercialization of VYNE's products and product candidates and other statements regarding the future

expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are

forward-looking statements. Any forward-looking statements are based on VYNE's current knowledge and its present

beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could

cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements.

These risks and uncertainties include, but are not limited to: the COVID-19 pandemic and its impact on our business

operations; adverse events associated with the commercialization of AMZEEQ and ZILXI; the outcome and cost of clinical trials

for current and future product candidates; determination by the FDA that results from VYNE's clinical trials are not

sufficient to support registration or marketing approval of product candidates; the outcome of pricing, coverage and

reimbursement negotiations with third party payors for AMZEEQ, ZILXI or any other products or product candidates that VYNE

may commercialize in the future; whether, and to what extent, third party payors impose additional requirements before

approving AMZEEQ and ZILXI prescription reimbursement; the eligible patient base and commercial potential of AMZEEQ, ZILXI or

any of VYNE's other products or product candidates; risks that VYNE's intellectual property rights, such as

patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted

narrowly or will not be infringed; risks that any of VYNE's patents may be held to be narrowed, invalid or

unenforceable or one or more of VYNE's patent applications may not be granted and potential competitors may also seek

to design around VYNE's granted patents or patent applications; additional competition in the acne and dermatology

markets; risks related to our indebtedness; inability to raise additional capital on favorable terms or at all; VYNE's

ability to recruit and retain key employees; and VYNE's ability to stay in compliance with applicable laws, rules and

regulations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause

VYNE's actual results to differ from those contained in the forward-looking statements, see the section titled

"Risk Factors" in VYNE's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as well as

discussions of potential risks, uncertainties, and other important factors in VYNE's subsequent filings with the U.S.

Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only

as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to

reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you

should not rely upon forward-looking statements as predictions of future events.

520 US Highway 22 - 2nd Floor - Bridgewater,